A study of 10,775 high-risk adult patients during the COVID-19 delta variant surge in late 2021 finds that treatment with one of three anti-spike neutralizing monoclonal antibodies for mild to moderate symptoms led to low rates of severe disease, hospitalization, ICU admission and mortality, according to researchers.
Click here for original story, Patients treated with monoclonal antibodies during COVID-19 delta surge had low rates of severe disease, study finds
Source: ScienceDaily